NCT05654623 · BASELINE
Baseline characteristics
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- denoms
- counts
- group Id
- BG000
- value
- 313
- group Id
- BG001
- value
- 311
- group Id
- BG002
- value
- 624
- units
- Participants
- groups
- description
- Participants were randomized to receive vepdegestrant 200 milligrams (mg) orally, once daily on Days 1 to 28 of each 28-day cycle. Participants continued to receive assigned treatment until objective disease progression, unacceptable toxicity, death, participant refused further treatment, or one of the other reasons for treatment discontinuation per protocol was met.
- id
- BG000
- title
- Vepdegestrant (ARV-471)
- description
- Participants were randomized to receive fulvestrant 500 mg, intramuscularly (injection) on Days 1 and 15 of Cycle 1 and then on Day 1 of each cycle starting from Cycle 2 Day 1, where 1 cycle = 28 days. Participants continued to receive assigned treatment until objective disease progression, unacceptable toxicity, death, participant refused further treatment, or one of the other reasons for treatment discontinuation per protocol was met.
- id
- BG001
- title
- Fulvestrant
- description
- Total of all reporting groups
- id
- BG002
- title
- Total
- measures
- classes
- categories
- measurements
- group Id
- BG000
- spread
- 12.09
- value
- 60.3
- group Id
- BG001
- spread
- 11.52
- value
- 60.3
- group Id
- BG002
- spread
- 11.8
- value
- 60.3
- dispersion Type
- STANDARD_DEVIATION
- param Type
- MEAN
- title
- Age, Continuous
- unit Of Measure
- Years
- classes
- categories
- measurements
- group Id
- BG000
- value
- 311
- group Id
- BG001
- value
- 310
- group Id
- BG002
- value
- 621
- title
- Female
- measurements
- group Id
- BG000
- value
- 2
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 3
- title
- Male
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Sex: Female, Male
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 29
- group Id
- BG001
- value
- 36
- group Id
- BG002
- value
- 65
- title
- Hispanic or Latino
- measurements
- group Id
- BG000
- value
- 241
- group Id
- BG001
- value
- 240
- group Id
- BG002
- value
- 481
- title
- Not Hispanic or Latino
- measurements
- group Id
- BG000
- value
- 43
- group Id
- BG001
- value
- 35
- group Id
- BG002
- value
- 78
- title
- Unknown or Not Reported
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Ethnicity (NIH/OMB)
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 4
- group Id
- BG002
- value
- 5
- title
- American Indian or Alaska Native
- measurements
- group Id
- BG000
- value
- 122
- group Id
- BG001
- value
- 129
- group Id
- BG002
- value
- 251
- title
- Asian
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- title
- Native Hawaiian or Other Pacific Islander
- measurements
- group Id
- BG000
- value
- 5
- group Id
- BG001
- value
- 6
- group Id
- BG002
- value
- 11
- title
- Black or African American
- measurements
- group Id
- BG000
- value
- 148
- group Id
- BG001
- value
- 143
- group Id
- BG002
- value
- 291
- title
- White
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- title
- More than one race
- measurements
- group Id
- BG000
- value
- 37
- group Id
- BG001
- value
- 29
- group Id
- BG002
- value
- 66
- title
- Unknown or Not Reported
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Race (NIH/OMB)
- unit Of Measure
- Participants
Complete source fields
- denoms
- counts
- group Id
- BG000
- value
- 313
- group Id
- BG001
- value
- 311
- group Id
- BG002
- value
- 624
- units
- Participants
- groups
- description
- Participants were randomized to receive vepdegestrant 200 milligrams (mg) orally, once daily on Days 1 to 28 of each 28-day cycle. Participants continued to receive assigned treatment until objective disease progression, unacceptable toxicity, death, participant refused further treatment, or one of the other reasons for treatment discontinuation per protocol was met.
- id
- BG000
- title
- Vepdegestrant (ARV-471)
- description
- Participants were randomized to receive fulvestrant 500 mg, intramuscularly (injection) on Days 1 and 15 of Cycle 1 and then on Day 1 of each cycle starting from Cycle 2 Day 1, where 1 cycle = 28 days. Participants continued to receive assigned treatment until objective disease progression, unacceptable toxicity, death, participant refused further treatment, or one of the other reasons for treatment discontinuation per protocol was met.
- id
- BG001
- title
- Fulvestrant
- description
- Total of all reporting groups
- id
- BG002
- title
- Total
- measures
- classes
- categories
- measurements
- group Id
- BG000
- spread
- 12.09
- value
- 60.3
- group Id
- BG001
- spread
- 11.52
- value
- 60.3
- group Id
- BG002
- spread
- 11.8
- value
- 60.3
- dispersion Type
- STANDARD_DEVIATION
- param Type
- MEAN
- title
- Age, Continuous
- unit Of Measure
- Years
- classes
- categories
- measurements
- group Id
- BG000
- value
- 311
- group Id
- BG001
- value
- 310
- group Id
- BG002
- value
- 621
- title
- Female
- measurements
- group Id
- BG000
- value
- 2
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 3
- title
- Male
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Sex: Female, Male
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 29
- group Id
- BG001
- value
- 36
- group Id
- BG002
- value
- 65
- title
- Hispanic or Latino
- measurements
- group Id
- BG000
- value
- 241
- group Id
- BG001
- value
- 240
- group Id
- BG002
- value
- 481
- title
- Not Hispanic or Latino
- measurements
- group Id
- BG000
- value
- 43
- group Id
- BG001
- value
- 35
- group Id
- BG002
- value
- 78
- title
- Unknown or Not Reported
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Ethnicity (NIH/OMB)
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 4
- group Id
- BG002
- value
- 5
- title
- American Indian or Alaska Native
- measurements
- group Id
- BG000
- value
- 122
- group Id
- BG001
- value
- 129
- group Id
- BG002
- value
- 251
- title
- Asian
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- title
- Native Hawaiian or Other Pacific Islander
- measurements
- group Id
- BG000
- value
- 5
- group Id
- BG001
- value
- 6
- group Id
- BG002
- value
- 11
- title
- Black or African American
- measurements
- group Id
- BG000
- value
- 148
- group Id
- BG001
- value
- 143
- group Id
- BG002
- value
- 291
- title
- White
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- title
- More than one race
- measurements
- group Id
- BG000
- value
- 37
- group Id
- BG001
- value
- 29
- group Id
- BG002
- value
- 66
- title
- Unknown or Not Reported
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Race (NIH/OMB)
- unit Of Measure
- Participants
Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0
Preserved source evidence · Not medical advice
Triangle